SAVI applicator removes obstacles associated with brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

There were no infections, persistent seromas, or local recurrences of cancer among any of the patients in two separate investigations conducted by Daniel Scanderbeg, PhD, and Catheryn Yashar, MD, both from the university's Moores Cancer Center. They presented their findings at the 2009 American Brachytherapy Society meeting. Dr. Scanderbeg's group retrospectively evaluated 13 breast cancer patients with breast cancer tumor cavities less than 7 mm from the skin surface.

Dr. Yashar's team reviewed early clinical experiences with SAVI in 40 breast cancer patients, nearly half of whom were not candidates for balloon brachytherapy due to skin spacing or small tumor size. They concluded that the device allowed for planning flexibility, easier insertion, and minimal exposure.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.